LOW-DOSE KETOCONAZOLE IN HORMONE REFRACTORY PROSTATE CANCER PATIENTS (HRPC): A SINGLE INSTITUTION EXPERIENCE

被引：0
|
作者：
Romero, J. [1 ]
Rodriguez, A. [1 ,2 ]
Villacampa, F. [1 ]
Duarte, J. M. [1 ]
Cabrera, F. [1 ]
Blanco, M. [1 ]
Sepulveda, J. [2 ]
Rodriguez, A. [1 ,2 ]
Castellano, D. [2 ]
Leiva, O. [1 ]
机构：
[1] Hosp Univ 12 Octubre, Dept Urol, Madrid, Spain
[2] Hosp Univ 12 Octubre, Dept Oncol, Madrid, Spain
来源：
EUROPEAN UROLOGY SUPPLEMENTS | 2009年 / 8卷 / 04期
关键词：
D O I：
10.1016/S1569-9056(09)60056-7
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：132 / 132
页数：1
相关论文
共 50 条
  • [41] Bi-weekly epirubicin, etoposide and low-dose dexamethasone for hormone-refractory prostate cancer
    Odrazka, K
    Vaculikova, M
    Petera, J
    Moravek, P
    Prosvic, P
    Zoul, Z
    Rydel, L
    Brodak, M
    Veselsky, Z
    Louda, M
    Simakova, E
    INTERNATIONAL JOURNAL OF UROLOGY, 2003, 10 (07) : 387 - 391
  • [42] Polyamine-reduced diet in metastatic hormone-refractory prostate cancer (HRPC) patients
    Cipolla, B
    Guillé, F
    Moulinoux, JP
    BIOCHEMICAL SOCIETY TRANSACTIONS, 2003, 31 : 384 - 387
  • [43] Willingness to pay for new hormone-refractory prostate cancer (HRPC) therapies: Experience from Ontario hospitals
    Milliken, D.
    Sawka, C.
    Trudeau, M. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [44] Weekly docetaxel for advanced hormone-refractory prostate cancer-HRPC
    Pepe, A.
    Usset, A.
    Calabria, C.
    Savio, G.
    Palmisano, V
    Leonardi, V
    Laudani, A.
    Arcuri, C.
    Giresi, A.
    Agostara, B.
    ANNALS OF ONCOLOGY, 2006, 17 : XI82 - XI82
  • [45] Cyclosporine and low-dose ketoconazole in renal transplant recipients:: A single-center experience
    Carbajal, H
    Soltero, L
    Rodríguez-Montalvo, C
    Valdés, A
    TRANSPLANTATION, 2004, 77 (07) : 1038 - 1040
  • [46] Vinorelbine (VNB) and estramustine (EMP) in hormone-refractory prostate cancer (HRPC).
    Ferraù, F
    Morgia, G
    Priolo, D
    Vitale, F
    Parisi, A
    Mattina, M
    Calì, S
    ANNALS OF ONCOLOGY, 2000, 11 : 77 - 77
  • [47] Phase II study of vinorelbine and low-dose docetaxel in chemotherapy-naive patients with hormone-refractory prostate cancer
    Koletsky, AJ
    Guerra, ML
    Kronish, L
    CANCER JOURNAL, 2003, 9 (04): : 286 - 292
  • [48] Advantages of Second Line Estramustine for Overall Survival of Hormone-Refractory Prostate Cancer (HRPC) Patients
    Naiki, Taku
    Okamura, Takehiko
    Kawai, Noriyasu
    Sakagami, Hiroshi
    Yamada, Yasuyuki
    Fujita, Keiji
    Akita, Hidetoshi
    Hashimoto, Yoshihiro
    Tozawa, Keiichi
    Kohri, Kenjiro
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2009, 10 (01) : 71 - 74
  • [49] Novel biological agents for the treatment of hormone-refractory prostate cancer (HRPC)
    Papatsoris, AG
    Karamouzis, MV
    Papavassiliou, AG
    CURRENT MEDICINAL CHEMISTRY, 2005, 12 (03) : 277 - 296
  • [50] Weekly docetaxel for advanced hormone-refractory prostate cancer-hrpc
    Pepe, A.
    Usset, A.
    Calabria, C.
    Savio, G.
    Palmisano, V
    Leonardi, V
    Laudani, A.
    Arcuri, C.
    Agostara, B.
    ANNALS OF ONCOLOGY, 2007, 18 : 187 - 187
12345